U of T, partner hospitals receive $85.9M for genomics research

On April 29th, John Milloy, the Minister of Research and Innovation visited the department of Chemistry to announce that U of T and its partners hospitals have been awarded a total of $63.8M by the Ministry of Research and Innovation's GL2 program, which supports significant research in genomics and gene-related areas.

Scott Tanner was one of the UoT researchers to win funding for his researchers. Last year, Tanner unveiled a first-in-class cell analysis instrument capable of determining up to 100 biomarkers in individuals cells. Using this technology, Tanner is now creating products that make it possible for doctors to diagnose disease and monitor treatments more effectively than ever before.

Massively Multi-parameter Single Cell Analysis by Mass Cytometry

We are proud to inform you that DVSSciences Inc. is now represented in Asia by IAS Inc.

Toronto, March 5th, 2010 – We are proud to inform you that DVSSciences Inc. is now represented in Asia by IAS Inc.

Ontario’s Technologies Show Considerable Promise

Toronto, January 13, 2010 – Dr. Morris (Mickey) Milner, President and CEO of The Health Technology Exchange (HTX), today announced the investment of over $1.7 million towards the development of seven emerging medical technologies.

Scott Tanner's presentation at the "Future of Medicine" conference
[ Windows Media Player ] [ QuickTime ]

DVS Sciences Unveils First-in-Class Mass Cytometer for Use in Understanding and Diagnosing Disease

Toronto, November 17, 2009 – Marking the culmination of six years of technology development research funded by Genome Canada through the Ontario Genomics Institute (OGI) and others, a Toronto research team unveiled a first-in-class analytical instrument at the recent Great Lakes International Imaging and Flow Cytometry Association annual meeting in Pittsburgh.

OICR invests $500,000 in new technology to identify cancer biomarkers

Toronto, July 21, 2008 – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced the investment of $500,000 in DVS Sciences Inc., for novel technology to facilitate the identification of biomarkers to study and diagnose cancer.